menu
    • menu
    [{"orgOrder":0,"company":"Bioma Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"LITHUANIA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Lactobacillus Acidophilus","moa":"||Gut Microbiome","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Bioma Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bioma Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bioma Health \/ Undisclosed"},{"orgOrder":0,"company":"Universidad San Francisco de Quito","sponsor":"Universidad Tecnol\u00f3gica Equinoccial | Biocodex","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ECUADOR","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Saccharomyces Boulardii","moa":"Immune","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Universidad San Francisco de Quito","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad San Francisco de Quito \/ Universidad Tecnol\u00f3gica Equinoccial | Biocodex","highestDevelopmentStatusID":"11","companyTruncated":"Universidad San Francisco de Quito \/ Universidad Tecnol\u00f3gica Equinoccial | Biocodex"},{"orgOrder":0,"company":"Universidad San Francisco de Quito","sponsor":"Biocodex | Neurodesarrollo Quito | University of Illinois, Urbana-Champaign","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ECUADOR","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Saccharomyces Boulardii","moa":"Immune","graph1":"Neurology","graph2":"Phase II","graph3":"Universidad San Francisco de Quito","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad San Francisco de Quito \/ Biocodex | Neurodesarrollo Quito | University of Illinois, Urbana-Champaign","highestDevelopmentStatusID":"8","companyTruncated":"Universidad San Francisco de Quito \/ Biocodex | Neurodesarrollo Quito | University of Illinois, Urbana-Champaign"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Saccharomyces Boulardii","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocodex \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Saccharomyces Boulardii

    Menu

    Saccharomyces Boulardii

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biocodex

                            France arrow
                            FNCE
                            Not Confirmed

                            Biocodex

                            France arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saccharomyces Boulardii

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

                            Details : Saccharomyces Boulardii is a Probiotic drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            September 11, 2025

                            Lead Product(s) : Saccharomyces Boulardii

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bioma Health

                            Lithuania arrow
                            FNCE
                            Not Confirmed

                            Bioma Health

                            Lithuania arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Acidophilus,Bifidobacterium Lactis,Saccharomyces Boulardii

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioma Probiotics Officially Launches: A Revolutionary Step Toward Total Gut Health

                            Details : Bioma Probiotics is a potent blend of prebiotics, probiotics, and postbiotics to help nourish the gut, reduce bloating, enhance energy, and support weight management.

                            Product Name : Bioma Probiotics

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            June 23, 2025

                            Lead Product(s) : Lactobacillus Acidophilus,Bifidobacterium Lactis,Saccharomyces Boulardii

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Universidad San Francisco de Quito

                            Country arrow
                            FNCE
                            Not Confirmed

                            Universidad San Francisco de Quito

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saccharomyces Boulardii

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Biocodex | Neurodesarrollo Quito | University of Illinois, Urbana-Champaign

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Probiotic Consumption in Children with Autism Spectrum Disorder (ASD)

                            Details : Saccharomyces Boulardii is a Probiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Autism Spectrum Disorder.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 23, 2024

                            Lead Product(s) : Saccharomyces Boulardii

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Biocodex | Neurodesarrollo Quito | University of Illinois, Urbana-Champaign

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Universidad San Francisco de Quito

                            Country arrow
                            FNCE
                            Not Confirmed

                            Universidad San Francisco de Quito

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saccharomyces Boulardii

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Universidad Tecnológica Equinoccial | Biocodex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Probiotics on the Fecal Resistome During Helicobacter Pylori Eradication Therapy

                            Details : Saccharomyces Boulardii is a Probiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            March 08, 2021

                            Lead Product(s) : Saccharomyces Boulardii

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Universidad Tecnológica Equinoccial | Biocodex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth